American Society of Nephrology
Sotagliflozin improved kidney and heart outcomes in patients with T2DM and CKD
Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease (CKD), adding to the drug's already known benefits for reducing both heart failure and ischemic events such as MI or stroke.
- Researchers analyzed data from the SCORED trial, a phase 3, double-blind, placebo-controlled study that randomized 10,584 patients with type 2 diabetes, CKD, and CV risk factors to receive sotagliflozin or placebo.
- Outcomes assessed included kidney and cardiorenal composites derived using laboratory values.
- Over a median follow-up of 16 months, 223 events were identified; sotagliflozin reduced the risk of the composite of sustained ≥50% decline in eGFR, eGFR <15 mL/min/1.73m^2, dialysis, or kidney transplant by 38%.
- Sotagliflozin also reduced the risk of a cardiorenal composite outcome (the above composite plus CV- or kidney-related death) by 23%.
Source:
(2023, October 30). American Society of Nephrology (ASN). Sotagliflozin Protects Kidney and Heart in Patients with Type 2 Diabetes and Chronic Kidney Disease. https://www.newswise.com/articles/sotagliflozin-protects-kidney-and-heart-in-patients-with-type-2-diabetes-and-chronic-kidney-disease